Remel, Inc. Issues Recall for Campy CVA Medium Over Bacterial Recovery Concerns
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Remel, Inc. is recalling specific lots of Campy CVA Medium after reports showed the product failed to properly recover Campylobacter Jejuni, potentially affecting lab results.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references AZ, CO, IL, NJ, OH, TN, WA. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, medical-device.
What Happened
Remel, Inc. has initiated a voluntary recall of its Campy CVA Medium (100/PK) following customer complaints. The reports indicate that the specific lot of medium showed low to no recovery of Campylobacter Jejuni ATCC 33291. This performance defect was identified through firm-initiated testing and feedback.
Which Products Are Affected
The recall involves 97 units of the following product:
- Product Name: Campy CVA Medium 100/PK, R01272
- Recall Number: Z-1474-2026
- UDI-DI: 848838001055
- Lot Numbers: R01272, lot 339135
- Expiration Date: January 12, 2026
The affected products were distributed to healthcare and laboratory facilities in Arizona, Colorado, Illinois, New Jersey, Ohio, Tennessee, and Washington.
What You Should Do
Laboratories and distributors should immediately check their inventory for the affected lot numbers. Remel, Inc. notified customers via letter on February 5, 2026. If you have the recalled product, you should follow the instructions provided in the notification letter regarding the quarantine and return of the items.
Why This Matters
The inability of the medium to recover the target pathogen, Campylobacter Jejuni, can lead to false-negative laboratory results. This poses a risk to patient health by potentially delaying or preventing the correct diagnosis of bacterial infections.
Source
Information provided by the FDA.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.